• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Press Media Release

press release distribution

  • Submit a Press Release
  • Market Wire
  • Make a Contribution
  • About
    • Template for press/media release
  • Contact

Data knowledge portal for Parkinson’s disease enables researchers to study complex data sets and perform genome-wide analyses

November 22, 2019 By admin Leave a Comment

Through a single data use agreement, researchers can today apply for access to the knowledge portal and interact with the entire data set here. The AMP PD Knowledge Portal contains data from cerebrospinal fluid, RNA, plasma and DNA samples previously collected through programs including The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and National Institute of Neurological Disorders and Stroke (NINDS) BioFIND Study, the Harvard Biomarkers Study of Brigham and Women’s Hospital and Massachusetts General Hospital, the NINDS Parkinson’s Disease Biomarkers Program, and MJFF’s Parkinson’s Progression Markers Initiative. Additionally, AMP PD provides a platform that can incorporate additional data sources and new types of data, including proteomics, a project already planned.

“AMP PD is a true example of the whole being greater than the sum of its parts,” said Walter Koroshetz, M.D., director, National Institute of Neurological Disorders and Stroke (NINDS). “The combination of many data sets could allow researchers greater power to analyze potential biomarkers for Parkinson’s disease. This effort follows other AMP programs which have the shared goal of changing the way we go about the business of studying disease.”

The Accelerating Medicines Partnership (AMP) program for Parkinson’s disease (PD) has launched a data portal to provide de-identified information collected from 4,298 PD patients and healthy controls to researchers working to develop effective therapies for the disease. The portal enables researchers to study complex data sets and perform genome-wide analyses at a scale previously impossible.

AMP PD is a public-private partnership between the National Institutes of Health, the U.S. Food and Drug Administration, with industry (Celgene, GSK, Pfizer, Sanofi and Verily) and non-profit (The Michael J. Fox Foundation for Parkinson’s Research) organizations and managed through the Foundation of the National Institutes of Health (FNIH). The goal of this partnership is to transform and accelerate drug development in PD by providing the expertise and support needed to determine which biomarkers show the greatest potential for predicting PD and the progression of the disease.

“One important part of this platform is that, in addition to providing a place for storing complex data, we are also providing the tools to analyze that data within the platform itself,” said Debra Babcock, M.D., Ph.D., program director at NINDS and co-chair of the AMP PD Steering Committee. “In this way, we are bringing scientists to the data, which will increase opportunities for collaboration.”

“The AMP model has provided a unique platform for bringing together diverse patient cohorts, advances in technology and scientific expertise to study Parkinson’s disease on a scale that has not been attempted before,” said David Wholley, Senior Vice President, Research Partnerships, FNIH. “With the AMP PD Knowledge Portal, we are helping the scientific community worldwide to fast-track discoveries that we hope will ultimately help Parkinson’s disease patients and their families.”

Over the past 18 months, AMP PD scientific teams have worked to ensure that the data added into the portal was accurate and described in a consistent way. This crucial step, called data harmonization, allows information gathered from different programs to be compared, and it also provides best practices for how to integrate new data provided by the community into the platform. One of the unique features of these data is that they are longitudinal – it will allow researchers to analyze data from across an individual’s lifespan or disease course.

About AMP PD: The Parkinson’s disease initiative is a part of the Accelerating Medicines Partnership, a joint venture between the National Institutes of Health, the U.S. Food and Drug Administration, six industry partners and one non-profit organization, managed by the Foundation for the NIH, to identify and validate promising biomarkers for Parkinson’s disease.

NINDS is the nation’s leading funder of research on the brain and nervous system. The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

About the Foundation for the National Institutes of Health: The Foundation for the National Institutes of Health (FNIH) creates and manages alliances with public and private institutions in support of the mission of the NIH. The FNIH works with its partners to accelerate biomedical research and strategies against diseases and health concerns in the United States and across the globe. Established by Congress in 1990, the FNIH is a not-for-profit 501(c)(3) charitable organization. For additional information about the FNIH, please visit fnih.org.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

Filed Under: Press Release Tagged With: Data knowledge portal, Parkinson’s disease

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Footer

Recent Posts

  • The Role of Forests in Climate Change Mitigation
  • U.S. Department of State, Bezos Earth Fund, and Rockefeller Foundation Announce Next Steps on Energy Transition Accelerator
  • Social Media Digest
  • COVID-19 Claims 2,000 Lives Per Week; 3 Critical Things Everyone Should Know
  • Economic Uncertainty Rising, 83% of Marketing Leaders to Prioritize Investments in Operational Efficiency and Hiring in 2023
  • PXEF.com adds new AI painting to art gallery: “Rich girl, poor girl in the swimming pool”
  • Market Research Media releases new market research report on the U.S. government market for low-code/no-code software
  • XRY, the MSAB extraction solution, comes with new features centered on ensuring the chain of custody of digital evidence
  • Ultisim Announces Advisory Board
  • Exclusive.org Announces Sale of Exclusive Domains

Media Partners

  • VPNW.com
  • OPINT
  • Digital Market
Picasso quote: When art critics get together…
Start today and make exercise a part of your daily routine
How to make free movement of services a reality?
Employee expectations have undergone a seismic shift
How to encourage creative behavior at work
Multi-Disciplined U.S. Air Force Leader Michael Newsom Joins System High as Vice President of Acquisitions and Operations
Orwellian: Kremlin will find a “final solution to the journalism question” in Russia
Rate for shipping a 40ft container from Shanghai to Los Angeles has now fallen by 38%
FDA Awards REI System $400M SIRCE IT Modernization Contract
Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
Countries with better FinTech development saw greater GDP resilience, employment during Covid-19: report
Bold new vision for the future of AI
CANON LEGENDS PARTNER WITH IMMUTABLE IMAGE TO CREATE NFTS FROM ICONIC PHOTOGRAPHS
Blockchain.com Rolls Out Crypto Trading in Oklahoma
Industry Briefs

Media Partners

  • Media Instances
  • PXEF.com
  • S3H.com
Blind People in a Public Bath, Utagawa Toyokuni (1769-1825), Tikotin Museum of Japanese Art
Pilates is booming again
Recession is here
The History and Significance of the Mona Lisa
European News Media Forum, November 10 2022
Wild Animals in The City
Japan today is a much more engaged partner in geopolitics
Halloween party
Volocopter’s 4-Seater Aircraft Takes First Flight
Happy Independence Day 2022
What are key features of the American innovation system to maintain U.S. global economic leadership
What is the role of religion in the modern world
Climate change-induced disasters are a stark reminder that investing in climate resilience is an imperative
What are we doing to mitigate climate change?
Winner-take-all: GAFA vs BATX

Copyright © 2022 PressMediaRelease.com

Sponsored by Exclusive Domains

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT